Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment
Wallach JD, Deng Y, McCoy RG, Dhruva SS, Herrin J, Berkowitz A, Polley EC, Quinto K, Gandotra C, Crown W, Noseworthy P, Yao X, Shah ND, Ross JS, Lyon TD. Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment. JAMA Network Open 2021, 4: e2130587. PMID: 34677594, PMCID: PMC8536955, DOI: 10.1001/jamanetworkopen.2021.30587.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsSecondary end pointsMyocardial infarctionClinical trialsCardiovascular diseaseProstate cancerCardiovascular eventsEnd pointRisk of MACELarge US administrative claims databasePropensity-matched cohort studyUS administrative claims databasePropensity score-matched patientsAdverse cardiovascular eventsPrimary end pointAdministrative claims databaseProportional hazards regressionRandomized clinical trialsAdministrative claims dataTrial eligibility criteriaMedicare Advantage beneficiariesProstate cancer treatmentReal-world evidenceElectronic health recordsCardiovascular outcomesComparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases
Singh S, Heien HC, Herrin J, Dulai PS, Sangaralingham L, Shah ND, Sandborn WJ. Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology And Hepatology 2021, 20: e74-e88. PMID: 33640480, PMCID: PMC8384969, DOI: 10.1016/j.cgh.2021.02.032.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseSerious infectionsMarginal structural Cox proportional hazards modelsCox proportional hazards modelBaseline disease characteristicsRetrospective cohort studyAdministrative claims databaseProportional hazards modelTime-varying useCohort studyBowel diseaseTreatment initiationUlcerative colitisHealthcare utilizationClaims databaseDisease characteristicsTumor necrosisVedolizumabLower riskHazards modelPatientsInfectionAntagonistInsurance coverageRisk